Tildrakizumab
drugOn this page
Also known as IlumetriIlumyaMK-3222SCH-900222Tildrakizumab asmnTildrakizumab-asmn
Summary
Tildrakizumab (CHEMBL2108681) is an approved antibody (ATC L04AC17); indicated across 5 conditions including psoriasis and immune system disorder.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Antibody
- ATC class: L04AC17
- Indications: 5 conditions
- Clinical trials: 24
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2108681 |
| Name | Tildrakizumab |
| Type | Antibody |
| Max phase | 4 |
| ATC | L04AC17 |
Also known as: Ilumetri, Ilumya, MK-3222, SCH-900222, Tildrakizumab, Tildrakizumab asmn, Tildrakizumab-asmn, TILDRAKIZUMAB
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
5 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| psoriasis | 4 | MONDO:0005083 | EFO:0000676 |
| immune system disorder | 4 | MONDO:0005046 | EFO:0000540 |
| neoplasm | 2 | MONDO:0005070 | MONDO:0004992 |
2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 24.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 7 |
| PHASE3 | 6 |
| Not specified | 6 |
| PHASE2 | 2 |
| PHASE2/PHASE3 | 1 |
| PHASE1/PHASE2 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT07352566 | PHASE4 | NOT_YET_RECRUITING | Utilization of a Microdevice for Psoriasis and Atopic Dermatitis |
| NCT04263610 | PHASE4 | COMPLETED | Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy |
| NCT04271540 | PHASE4 | COMPLETED | MIcrovascular dysfuNction In Moderate-severe Psoriasis |
| NCT04339595 | PHASE4 | TERMINATED | Long-Term Treatment Effect With Tildrakizumab in Participants With Plaque Psoriasis |
| NCT04340076 | PHASE4 | COMPLETED | Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis |
| NCT04541329 | PHASE4 | COMPLETED | Predicting Inflammatory Skin Disease Response to IL-23 Blockade |
| NCT05110313 | PHASE4 | COMPLETED | Effects of Tildrakizumab on Epigenetic Age |
| NCT03997786 | PHASE2/PHASE3 | ACTIVE_NOT_RECRUITING | A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis |
| NCT06611163 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis. |
| NCT01722331 | PHASE3 | COMPLETED | A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010) |
| NCT01729754 | PHASE3 | COMPLETED | A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011) |
| NCT01936688 | PHASE3 | WITHDRAWN | A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous MK-3222 in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-012) |
| NCT03897075 | PHASE3 | COMPLETED | Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis |
| NCT05108766 | PHASE3 | COMPLETED | A Phase Ⅲ Study to Evaluate Tildrakizumab in the Treatment of Chinese Subjects With Moderate to Severe Plaquetype Psoriasis |
| NCT01225731 | PHASE2 | COMPLETED | A Study to Determine the Optimal Dose of Tildrakizumab (SCH 900222/MK-3222) for the Treatment of Moderate-to-severe Chronic Plaque Psoriasis (P05495) (MK-3222-003) |
| NCT04112810 | PHASE2 | COMPLETED | Tildrakizumab for Prevention of Acute Graft-Versus-Host Disease |
| NCT04458311 | PHASE1/PHASE2 | TERMINATED | Abiraterone Acetate in Combination With Tildrakizumab |
| NCT04971200 | EARLY_PHASE1 | COMPLETED | Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo |
| NCT06029257 | Not specified | RECRUITING | A Study of Tildrakizumab in the Treatment of Genital Psoriasis (CZATCH-Genital-PsO) |
| NCT06030076 | Not specified | RECRUITING | A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis |
| NCT06488170 | Not specified | ACTIVE_NOT_RECRUITING | A Study to Assess Patient-Reported Wellbeing Using Tildrakizumab in a Live Setting |
| NCT07244744 | Not specified | ACTIVE_NOT_RECRUITING | Tilrdakizumab Almirall |
| NCT04203693 | Not specified | COMPLETED | Observational Study of Tildrakizumab in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice |
| NCT04823247 | Not specified | COMPLETED | Observational Real-world Evidence (RWE) Study to Assess Patient-reported Wellbeing Using Tildrakizumab in Live Setting - POSITIVE Study |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: psoriasis, immune system disorder